FDA authorizes second genome sequencing test for SARS-CoV-2
![FDA-guidance](/sites/default/files/styles/900x400/public/2018-07/FDA-guidance.jpg?itok=I8jaZmAO)
The Food and Drug Administration recently issued an emergency use authorization for a next generation sequencing test to detect SARS-CoV-2 in respiratory specimens from individuals suspected of COVID-19 by their health care provider.
Laboratories certified under the Clinical Laboratory Improvement Amendments to perform high complexity tests can perform the SARS-CoV-2 NGS Assay test. For more information, see the fact sheet for health care providers.
Related News Articles
Headline
The Centers for Disease Control and Prevention's COVID-19 data tracker shows an 18.1% test positivity rate for the week ending Aug. 10, the highest it has been…
Headline
The Centers for Disease Control and Prevention Aug. 13 issued an advisory alerting of an uptick of cases of parvovirus B19 across the U.S. Parvovirus B19 is a…
Blog
The RAND Corporation recently released the fifth iteration of its biannual hospital price report. The AHA has previously highlighted significant flaws with…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…